Table 5.
Summary of treatment withdrawals and number of O-FC courses completed
| Number of courses received and reason for treatment withdrawal | No. of patients |
||
|---|---|---|---|
| Ofatumumab 500 mg (n = 31) | Ofatumumab 1000 mg (n = 30) | Total (N = 61) | |
| Did not receive 6 courses of O-FC | 9 | 13 | 22 |
| Received 3 or fewer courses of O-FC due to: | |||
| Cytopenias | 2 | 3 | 5 |
| AIHA | 1 | 1 | |
| Nonresponse | 2 | 1 | 3 |
| Patient request | 1 | 1 | |
| Myocardial infarction | 1 | 1 | |
| Chest discomfort | 1 | 1 | |
| Death | 1 | 1 | |
| Received 4-5 courses of O-FC due to: | |||
| Cytopenias | 1 | 4* | 5* |
| AIHA | 1 | 1 | 2 |
| Investigator decision | 1 | 1 | |
| Patient request | 1 | 1 | |
AIHA indicates autoimmune hemolytic anemia.
*
Two patients in the 1000-mg cohort received all 6 infusions of ofatumumab but no fludarabine and cyclophosphamide during treatment course 6 due to cytopenias.